Nasal delivery of peptides is gaining ground as a practical alternative to injections. The nose offers a direct path to the bloodstream and even the brain, making it an exciting route for peptide drugs.
For biotech companies, developing a nasal peptide product requires specialized expertise that most teams do not have in-house. Outsourcing to the right CDMO partner can save years of development time and millions in costs.
- Nasal peptide delivery achieves 10-50% bioavailability while avoiding first-pass liver metabolism and offering a unique nose-to-brain transport pathway.
- Modern absorption enhancers are the single most critical formulation factor, boosting nasal peptide bioavailability to levels approaching subcutaneous injection.
- Evaluate CDMO partners on nasal-specific expertise, device selection capabilities, and regulatory experience before outsourcing peptide spray development.
- Device selection directly impacts dose accuracy and patient compliance, so choose between multi-dose and single-dose formats based on your therapeutic use case.
- Plan for 3-5 year development timelines and budget for specialized regulatory tests including nasal tissue irritation and mucociliary clearance studies.
- Secure intellectual property early by defining ownership of formulation data, device designs, and manufacturing processes in your CDMO contract.
- Nasal peptide delivery achieves 10-50% bioavailability while avoiding first-pass liver metabolism and offering a unique nose-to-brain pathway.
- Modern absorption enhancers are the single most critical formulation factor, capable of boosting nasal peptide bioavailability to near-injection levels.
- Evaluate CDMO partners on nasal-specific expertise, device selection capabilities, and regulatory track record before committing to outsourcing.
- Device choice directly impacts dose accuracy and patient compliance, so select spray hardware early in the development process.
- Expect 3-5 years from formulation through regulatory approval, with device-drug compatibility testing often driving timeline delays.
- Secure IP agreements covering formulation techniques and device integration before sharing proprietary peptide data with any CDMO partner.
Why Nasal Delivery for Peptides?
The nasal cavity has a rich blood supply and a thin tissue barrier. These features allow peptides to cross into the bloodstream quickly, often within minutes of administration.
Patients also prefer nasal sprays over injections. Better patient compliance means better real-world outcomes, which is increasingly important for drug approval and commercial success.
Nasal vs. Other Delivery Routes for Peptides
| Feature | Nasal Spray | Subcutaneous Injection | Oral Tablet |
|---|---|---|---|
| Bioavailability | 10-30% (with enhancers up to 50%) | 60-100% | Less than 2% for most peptides |
| Onset of Action | 5-15 minutes | 15-30 minutes | 30-60 minutes |
| Patient Compliance | High | Moderate | Highest |
| Self-Administration | Easy | Requires training | Easy |
| Cold Chain Needs | Sometimes | Often | Rarely |
| Brain Delivery | Possible (nose-to-brain) | No | No |
| Pain/Discomfort | Minimal | Moderate | None |
According to a 2025 study published in the Journal of Controlled Release, nasal peptide delivery with modern absorption enhancers achieved bioavailability levels of 30-50% for peptides up to 40 amino acids long, approaching the levels seen with subcutaneous injection. Source: ScienceDirect
Lisbeth Illum, Professor of Pharmaceutical Sciences, Advanced Drug Delivery Reviews: "The nasal route offers a practical, non-invasive alternative for peptide delivery, with absorption enhancers now capable of achieving bioavailability that rivals subcutaneous injection"
Bioavailability Advantages of Nasal Peptide Delivery
The nasal route avoids first-pass metabolism in the liver. When peptides are swallowed, the liver breaks down most of the drug before it reaches the rest of the body, but nasal delivery skips this step entirely.
The nasal mucosa also has lower levels of proteolytic enzymes compared to the gut. This means peptides survive longer in the nasal cavity, giving them more time to cross into the bloodstream.
Nose-to-Brain Delivery
One of the most exciting features of nasal delivery is the potential for direct nose-to-brain transport. The olfactory and trigeminal nerves connect the nasal cavity directly to the brain.
Peptide drugs for neurological conditions like Alzheimer's disease, Parkinson's disease, and migraines can potentially reach the brain faster and at higher concentrations through nasal delivery. This pathway bypasses the blood-brain barrier, which blocks most drugs from entering the brain.
"Nose-to-brain delivery is no longer theoretical. We have clear evidence from clinical studies that peptides administered nasally can reach brain tissue at meaningful concentrations. For companies developing CNS-targeted peptide therapeutics, the nasal route should be at the top of the list. The key is finding the right formulation that maximizes transport along the olfactory pathway."
The human nasal cavity has a surface area of about 150 square centimeters lined with highly vascularized tissue, which is why some nasal peptide formulations reach peak blood levels in under 15 minutes.
Formulation Challenges for Nasal Peptide Sprays
Developing a nasal peptide spray is not as simple as putting a peptide solution in a spray bottle. Multiple technical challenges must be solved to create a product that works reliably.
Peptide stability in solution is the first hurdle. Many peptides degrade quickly in water, so the formulation must include stabilizers that protect the peptide without irritating the nasal tissue.
Key Formulation Challenges
| Challenge | Impact | Solution Approaches |
|---|---|---|
| Peptide instability | Short shelf life, loss of potency | Lyophilized reconstitution, stabilizing excipients |
| Low absorption | Poor bioavailability | Absorption enhancers, mucoadhesives |
| Mucociliary clearance | Drug removed too quickly | Bioadhesive polymers, gel-forming systems |
| Nasal irritation | Poor patient tolerance | pH buffering, gentle preservatives |
| Dose uniformity | Inconsistent dosing | Device engineering, viscosity optimization |
| Microbial growth | Contamination risk | Preservatives, multi-dose device design |
Absorption Enhancers: The Key to Success
Absorption enhancers are compounds added to the formulation that temporarily open the tight junctions between nasal cells. This allows larger peptide molecules to pass through the tissue barrier.
Common enhancers include alkylsaccharides, cyclodextrins, and fatty acid derivatives. The challenge is finding enhancers that boost absorption enough without causing damage to the nasal lining over time.
Modern tight-junction-opening enhancers can increase nasal peptide absorption by 10 to 50 times compared to unenhanced formulations, all while being safe enough for daily use over months or years.
Choosing a CDMO Partner for Nasal Peptide Development
Selecting the right contract development and manufacturing organization (CDMO) is one of the most important decisions in a nasal peptide program. The wrong partner can add years of delays and millions in extra costs.
Not all CDMOs have experience with nasal formulations, and even fewer have worked with peptide-specific nasal products. You need a partner who understands both the peptide and the delivery device.
CDMO Evaluation Criteria
| Criteria | What to Look For | Red Flags |
|---|---|---|
| Nasal formulation track record | Multiple products developed, clinical experience | Only oral/injectable experience |
| Peptide handling expertise | Temperature-controlled facilities, stability testing | No peptide-specific capabilities |
| Device partnerships | Relationships with nasal device manufacturers | No device development experience |
| Analytical capabilities | Nasal-specific testing (deposition, spray pattern) | Generic testing only |
| Regulatory experience | FDA/EMA nasal product submissions | No regulatory submissions on file |
| Scale-up capability | Pilot to commercial manufacturing | Lab-scale only |
| Quality systems | GMP certification, audit history | No recent regulatory inspections |
"When evaluating a CDMO for nasal peptide work, ask to see their data on absorption enhancer compatibility with peptides. Many enhancers that work well for small molecules can actually destabilize peptides. A good CDMO will have screened multiple enhancer systems and will know which ones play well with different peptide classes."
The Nasal Spray Device: More Than Just a Bottle
The spray device is a critical part of the product. It determines droplet size, spray pattern, and dose accuracy, all of which affect how well the drug works.
For peptide nasal sprays, the device must produce droplets between 30 and 120 microns. Droplets that are too large will drip out of the nose, and droplets that are too small will be inhaled into the lungs.
Common Nasal Spray Device Types
| Device Type | Doses | Preservation | Best For |
|---|---|---|---|
| Multi-dose pump | 60-200 sprays | Chemical preservative | Chronic daily use |
| Preservative-free pump | 60-200 sprays | Mechanical barrier | Sensitive peptides |
| Unit-dose device | 1-2 sprays | Sealed container | Emergency/acute use |
| Bi-dose device | 2 sprays (one per nostril) | Sealed container | Single-treatment doses |
| Powder device | 1-4 doses | No preservative needed | Unstable peptides |
Companies exploring nasal peptide delivery should also consider how this approach fits within the broader landscape of oral peptide delivery advances to determine which route is best for their specific molecule.
Before signing with a CDMO, request their device compatibility testing data for at least two spray platforms, since device-peptide interactions are the most common source of unexpected delays in nasal formulation programs.
Development Timeline for Nasal Peptide Products
Developing a nasal peptide spray from concept to clinical trial takes careful planning. Each phase has specific milestones that must be met before moving forward.
A typical program takes 24 to 36 months from formulation development to Phase I clinical trial readiness. Rushing this timeline usually leads to costly reformulation later.
Development Phases and Timelines
| Phase | Activities | Duration | Cost Range |
|---|---|---|---|
| Feasibility | Peptide stability, enhancer screening, prototype formulations | 3-6 months | $200K-$500K |
| Optimization | Lead formulation selection, device selection, short-term stability | 6-9 months | $500K-$1.5M |
| Scale-up | Process development, analytical method validation, pilot batches | 6-12 months | $1M-$3M |
| GMP Manufacturing | Clinical supply production, release testing, stability studies | 6-9 months | $1.5M-$4M |
| IND Preparation | Regulatory writing, toxicology, clinical protocol | 3-6 months | $500K-$2M |
Regulatory Requirements for Nasal Peptide Products
Nasal drug products have specific regulatory requirements beyond those for standard injectable peptides. The FDA and EMA both have detailed guidance on nasal spray product development.
Key regulatory tests include spray pattern analysis, droplet size distribution, pump delivery uniformity, and container closure integrity. These tests must be performed using validated methods.
Critical Regulatory Tests
| Test | Purpose | Acceptance Criteria |
|---|---|---|
| Delivered dose uniformity | Consistent dosing across all sprays | USP <601> requirements |
| Spray pattern | Even distribution in the nose | Defined ovality and area |
| Droplet size distribution | Proper deposition in nasal cavity | D50 between 30-120 microns |
| Priming and repriming | Device readiness after non-use | Consistent after specified actuations |
| Leachables and extractables | Safety of device materials | Below safety thresholds |
| Weight loss over time | Container closure integrity | Within specification over shelf life |
Cost Considerations for Outsourced Nasal Peptide Development
Outsourcing nasal peptide development is a significant investment, but it is typically far less expensive than building internal capabilities. Understanding the cost structure helps with budgeting and investor communications.
Total outsourced development costs from feasibility through clinical supply typically range from $3 million to $10 million. The wide range reflects differences in peptide complexity, device requirements, and regulatory strategy.
Building an in-house nasal spray development and manufacturing facility from scratch costs $15 million to $30 million and takes 18 to 24 months, making outsourcing the clear choice for most biotech companies at the clinical stage.
Intellectual Property Considerations
Nasal peptide formulations offer multiple layers of intellectual property protection. The peptide itself, the formulation composition, the absorption enhancer system, and the device can all be patented separately.
Working with a CDMO that respects IP boundaries is essential. Clear agreements about IP ownership, confidentiality, and publication rights should be in place before any work begins.
Building a strong team with peptide formulation expertise is critical for managing outsourced nasal development programs effectively. Many companies find that investing in a skilled peptide manufacturing team helps them get more value from their CDMO relationships.
Selecting the right absorption enhancer and device combination early in development is the single biggest factor in whether a nasal peptide program hits its bioavailability and timeline targets.
FAQs
What peptides are best suited for nasal delivery?
Peptides between 5 and 40 amino acids long with molecular weights under 5,000 daltons tend to work best for nasal delivery. Larger peptides can also be delivered nasally with the right absorption enhancers, but bioavailability decreases with increasing size.
How does nasal peptide bioavailability compare to injection?
With modern absorption enhancers, nasal bioavailability for peptides typically reaches 10-50% of the injected dose. While this is lower than injection, it is dramatically higher than oral delivery and is sufficient for many therapeutic applications.
Can nasal peptide sprays be used for chronic daily treatment?
Yes, several marketed nasal peptide products are approved for daily chronic use. The key is ensuring that the formulation does not irritate or damage the nasal mucosa with long-term use. Preservative-free formulations are generally preferred for chronic applications.
How do you test nasal peptide products for regulatory submission?
Regulatory testing includes delivered dose uniformity, spray pattern analysis, droplet size distribution, and stability studies. Additional tests specific to peptides include potency assays, purity analysis, and degradation product identification.
What is the typical shelf life for a nasal peptide spray?
Most nasal peptide sprays target a shelf life of 18 to 24 months. Achieving this requires careful formulation with appropriate stabilizers and sometimes cold storage conditions. Some lyophilized nasal powder products can achieve longer shelf lives.
Is it better to use a multi-dose or single-dose nasal device for peptides?
The choice depends on the clinical application. Multi-dose devices are better for chronic daily use because they are more convenient and cost-effective. Single-dose devices are preferred for emergency or acute-use products where precise dosing and sterility are critical.
Conclusion
Nasal peptide delivery offers a compelling combination of good bioavailability, patient convenience, and the unique potential for nose-to-brain transport. For biotech companies with peptide drug candidates, the nasal route deserves serious consideration.
Outsourcing formulation development to an experienced CDMO is the most efficient path forward for most companies. By choosing the right partner and planning carefully, biotech teams can bring nasal peptide products to clinical trials faster and with less risk than going it alone.
Topics
Dr. Lisa Park
Regulatory Affairs Specialist
PharmD | 9 years in peptide pharmaceutical compliance
Focuses on FDA, DEA, and state pharmacy board regulations governing peptide compounds. Guides compounding pharmacies and peptide manufacturers through changing compliance landscapes.
Reviewed by Dr. Lisa Park, PharmD, April 2026